Chevy Chase Trust Holdings, Inc. Nektar Therapeutics Transaction History

Chevy Chase Trust Holdings, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 12, 2020	SELL	$15.87 - $23.12 $2.27 Million - $3.3 Million	-142,807 Closed	0 $0
Q3 2019 Nov 20, 2019	BUY	$16.91 - $36.27 $13,849 - $29,705	819 Added 0.58%	142,807 $2.6 Million
Q2 2019 Aug 14, 2019	BUY	$31.0 - $36.3 $8,897 - $10,418	287 Added 0.2%	141,988 $5.05 Million
Q1 2019 May 13, 2019	SELL	$31.58 - $46.35 $22,232 - $32,630	-704 Reduced 0.49%	141,701 $4.54 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $25,530 - $47,529	839 Added 0.59%	142,405 $4.68 Million
Q3 2018 Oct 23, 2018	BUY	$46.46 - $68.49 $281,640 - $415,186	6,062 Added 4.47%	141,566 $8.63 Million
Q2 2018 Aug 02, 2018	SELL	$46.25 - $104.45 $22,246 - $50,240	-481 Reduced 0.35%	135,504 $6.62 Million
Q1 2018 Apr 10, 2018	BUY	$57.4 - $108.44 $7.81 Million - $14.7 Million	135,985 New	135,985 $14.5 Million

16.1M

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $10.7B
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Chevy Chase Trust Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Chevy Chase Trust Holdings, Inc. with notifications on news.